|Biotech Due Diligence||
It's back! Enjoy another round-up of the news items and SEC filings that these biotech and pharmaceutical companies hoped we didn't see...
Apologies for the lag, but as a result I have a long list of intriguing and influential articles teed up. Enjoy the latest collection here.
How a Rundown Square Near Boston Birthed a Biotech Boom and Real Estate Empire
Rebecca Spalding (Bloomberg)
Fear Of The Flood: Post-IPO Lockup Expiry In Biotech
Bruce Booth (LifeSciVC)
No, LaCroix Isn’t Poisoning You Like You’re A Giant Cockroach
Christie Aschwanden (FiveThirtyEight)
Where Do Recent Small Molecule Clinical Candidates Come From?
Dennis Hu (Drug Hunter)
Two sick children and a $1.5 million bill: One family’s race for a gene therapy cure
Antonio Regalado (MIT Technology Review)
Drug Repurposing, Computed
Derek Lowe (In the Pipeline)
The best of Bio-Twitter highlight what's new and notable in the scientific and medical literature.
For the second straight September, BiotechDueDiligence is recognizing Pediatric Cancer Awareness Month!
Your support is greatly appreciated